

ASX Announcement

Medibio Limited – 17 June 2019



Joint Venture Dispute

Melbourne, Australia and Minneapolis, MN – 17 June 2019: Medibio Limited (MEB or the Company)(ASX: MEB)(OTCQB: MDBIF), a health technology company today announces that it has received a writ of summons issued in the Supreme Court of Western Australia.

The writ relates to a joint venture agreement that was executed in April 2017 by the Company's previous management.

The claim states the Company wrongfully terminated the joint venture agreement and as a result the joint venture partner was unable to perform its obligations under the agreement because of the Company's conduct.

The writ does not specify the amount of any damages being sought. To date the applicant has failed to substantiate that they have performed their obligations under the joint venture agreement. The Company intends to vigorously defend the claims made in the writ.

– END –

About Medibio Limited

Medibio (ASX: MEB) (OTCQB: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.

Further Information:	Website: www.medibio.com.au
Medibio Media Enquiries: Kristi Hamilton Director, Strategic Communications Medibio Limited kristi.hamilton@medibio.com.au T: +1 952 232 0934	Australian Investor Enquiries: Peter Taylor NWR Communications peter@nwrcommunications.com.au T: +61 (0) 412 036 231